Seawolf Therapeutics launched Monday with $100 million in Series A funding and a partnership with Sanofi valued at up to $1.2 billion to advance DNA-based medicines. The financing round for the United States drug developer was backed by Versant Ventures, MPM BioImpact, and Novartis AG-REG's venture fund. The deal gives the France-based pharmaceutical giant access to non-viral gene delivery systems for bleeding disorders and other conditions.

The TRIDENT Delivery Platform